HomeALTME • EPA
add
TME Pharma NV
Previous close
€0.26
Day range
€0.24 - €0.25
Year range
€0.19 - €1.99
Market cap
6.80M EUR
Avg Volume
751.81K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2023info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.39M | -63.98% |
Net income | -1.83M | 64.57% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.35M | 64.85% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.01M | -62.37% |
Total assets | 3.46M | -58.20% |
Total liabilities | 3.62M | -40.15% |
Total equity | -163.00K | — |
Shares outstanding | 5.30M | — |
Price to book | -8.50 | — |
Return on assets | -100.52% | — |
Return on capital | -160.59% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2023info | Y/Y change |
|---|---|---|
Net income | -1.83M | 64.57% |
Cash from operations | -1.70M | 42.07% |
Cash from investing | -9.50K | -137.50% |
Cash from financing | 895.00K | -59.47% |
Net change in cash | -813.00K | -11.14% |
Free cash flow | -743.75K | 66.66% |
About
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Founded
1997
Website
Employees
13
